Evinacumab-dgnb
Class: Antilipemic Agents, Miscellaneous
Brands: Evkeeza
Introduction
Evinacumab-dgnb is an antilipemic agent.
Uses for Evinacumab-dgnb
Evinacumab-dgnb has the following uses:
Evinacumab-dgnb is an angiopoietin-like protein 3 (ANGPTL3) inhibitor indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH).
Evinacumab-dgnb has the following limitations of use:
The safety and effectiveness of evinacumab-dgnb have not been established in patients with other causes of hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH).
The effects of evinacumab-dgnb on cardiovascular morbidity and mortality have not been determined.
Evinacumab-dgnb Dosage and Administration
General
Evinacumab-dgnb is available in the following dosage form(s) and strength(s):
Injection: 345 mg/2.3 mL (150 mg/mL) and 1,200 mg/8 mL (150 mg/mL) solution in single-dose vials.
Dosage
It isessentialthat the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:
Pediatric Patients
Dosage and Administration
The recommended dose of evinacumab-dgnb is 15 mg/kg administered by intravenous (IV) infusion once monthly (every 4 weeks).
See the Full Prescribing Information for preparation instructions for the IV infusion.
Administer the diluted solution via IV infusion over 60 minutes through an IV line containing a sterile, in-line or add-on, 0.2 micron to 5 micron filter.
Do not mix other medications with evinacumab-dgnb or administer other medications concomitantly via the same infusion line.
The rate of infusion may be slowed, interrupted or discontinued if the patient develops any signs of adverse reactions, including infusion or hypersensitivity reactions.
Adults
Dosage and Administration
The recommended dose of evinacumab-dgnb is 15 mg/kg administered by IV infusion once monthly (every 4 weeks).
See the Full Prescribing Information for preparation instructions for the IV infusion.
Administer the diluted solution via IV infusion over 60 minutes through an IV line containing a sterile, in-line or add-on, 0.2 micron to 5 micron filter.
Do not mix other medications with evinacumab-dgnb or administer other medications concomitantly via the same infusion line.
The rate of infusion may be slowed, interrupted or discontinued if the patient develops any signs of adverse reactions, including infusion or hypersensitivity reactions.